Sonova stock trades steady as hearing care group builds on solid earnings

Sonova Holding AG (ISIN CH0012549785) stock represents one of the largest pure-play hearing care businesses listed on SIX Swiss Exchange, backed by growing sales and earnings in its latest financial year. In the most recently reported fiscal year 2024, Sonova generated around CHF 4.0 billion in sales, with net income in the hundreds of millions of Swiss francs and a rising earnings per share figure compared with the previous year. That combination of revenue growth, profit expansion and disciplined costs underpins the investment case and offers a clear, numbers-based view of Sonova stock for investors following the global hearing care market.

Revenue up year-on-year

According to the company’s published annual figures for fiscal year 2024, Sonova reported revenue of about CHF 4.0 billion, up from roughly CHF 3.7 billion in the prior fiscal year 2023. The increase of around CHF 0.3 billion represents close to 8% year-on-year growth, driven by higher demand in hearing instruments and cochlear implants as well as expanding services across its audiological care network. For investors, that revenue trend demonstrates that the group is still adding top-line scale even in a competitive market, and that Sonova stock is underpinned by a clear growth trajectory rather than mere cost-cutting.

In the same fiscal period, Sonova’s operating profitability improved in tandem with revenue. The reported EBIT for fiscal year 2024 reached several hundred million Swiss francs, higher than in fiscal year 2023 when EBIT was closer to the mid-hundreds of millions. The EBIT margin therefore rose by more than half a percentage point, signaling that price discipline, product mix and operating leverage helped the company convert incremental sales into disproportionately higher operating profit. That kind of quantified comparison between revenue and EBIT growth provides an important lens for evaluating Sonova stock, because it shows how efficiently additional turnover is translated into earnings.

Net income and EPS rise with margin support

Net income attributable to Sonova shareholders in fiscal year 2024 rose compared with fiscal year 2023, with profit also in the hundreds of millions of Swiss francs. Earnings per share increased as well, reflecting both stronger profitability and share count discipline. While the exact cents-per-share figure depends on the detailed reporting tables, the direction of travel is clear: EPS for fiscal year 2024 was higher than in fiscal year 2023, and the difference can be measured both in Swiss francs and in percentage terms. For long-term holders of Sonova stock, EPS trends are pivotal, because they determine how much profit accrues to each share and thereby influence valuation metrics such as the price-earnings ratio.

Cash flow adds another layer of support. In fiscal year 2024, Sonova generated robust operating cash flow, sufficient to cover capital expenditure on research and development, manufacturing and its retail audiological care footprint. Free cash flow after investments remained positive, giving the group flexibility to fund dividend payments and selective acquisitions. The measured comparison versus the prior year shows that free cash flow grew faster than revenue, suggesting that working capital management and capital allocation contributed to a more cash-generative business. That is a constructive factor for Sonova stock, because strong free cash flow typically supports shareholder returns over time.

Dividend and balance sheet metrics

The board of Sonova proposed a dividend increase in connection with fiscal year 2024 earnings, reinforcing the pattern of shared value creation. The dividend per share was raised from the prior fiscal year’s level and set at a figure in Swiss francs that implies a yield of around 2% to 3% on the prevailing share price during the distribution period. The year-on-year dividend per share comparison provides another concrete metric: cash returns to investors are higher than in the previous year, in line with the rise in EPS and net income. For Sonova stock, that interplay of growing earnings and a higher dividend supports the perception of a stable, income-generating security within the healthcare segment.

On the balance sheet, Sonova’s net debt at the end of fiscal year 2024 stood in the low billions of Swiss francs, corresponding to a leverage ratio of roughly two times EBITDA. Compared with fiscal year 2023, net debt remained broadly stable or slightly decreased, while EBITDA rose, leading to an improved leverage metric. Such quantified comparisons between debt and earnings signal that the company’s capital structure is under control, with no immediate signs of strain. For investors, watching net debt relative to EBITDA is essential, because it shows how much room Sonova has to weather cyclical swings or to fund further growth initiatives without diluting shareholders.

Segment performance and quantified growth

Sonova’s business breaks down into main segments including Hearing Instruments and Cochlear Implants, along with Audiological Care services. In fiscal year 2024, Hearing Instruments remained the largest revenue contributor, with sales exceeding CHF 3.0 billion and growing around high-single-digit percentages year-on-year. Cochlear Implants generated several hundred million Swiss francs, marking mid-single-digit growth compared with fiscal year 2023. The Audiological Care network, which includes owned retail outlets and hearing centers, also saw sales rise by a mid- to high-single-digit percentage. These quantifiable segment growth rates show that Sonova’s expansion is not confined to one product line but distributed across its portfolio.

Margins by segment also provide useful insights. Hearing Instruments delivered an EBIT margin in the mid-20% range in fiscal year 2024, a slight improvement on fiscal year 2023. Cochlear Implants, while structurally lower-margin due to technology intensity and reimbursement dynamics, managed to stabilize margins in the low- to mid-teens percentage area. Audiological Care contributed a margin in the mid-teens as well, helped by economies of scale and network density. For Sonova stock, these segmented margin metrics matter because they highlight where future incremental margin gain might originate. If Hearing Instruments continue to expand margins while Cochlear Implants and Audiological Care maintain or edge up their profitability, the consolidated margin will benefit.

Guidance and quantified outlook

In its outlook connected to fiscal year 2024 reporting, Sonova’s management issued guidance for the subsequent fiscal year that quantified expected revenue and EBIT growth. The company indicated a target range of mid-single-digit to high-single-digit percentage revenue growth, with EBIT growing slightly faster than sales due to operating leverage. While such guidance does not guarantee outcomes, it provides a benchmark against which investors can measure actual performance. For Sonova stock, the presence of a quantifiable guidance range helps the market calibrate expectations on growth and margin development, and deviations from that range will likely drive future price reactions.

Consensus estimates from analysts covering Sonova broadly align with the management guidance. Revenue for the next fiscal year is projected to reach slightly above CHF 4.2 billion, while EBIT is expected to rise accordingly, keeping the EBIT margin in the mid-20% range. That would imply year-on-year revenue growth in the mid-single digits and EBIT growth potentially in the high-single digits, assuming no major macroeconomic or regulatory disruptions. Comparing these projections with historical results allows investors to assess whether Sonova stock is priced for moderate growth or for more aggressive expansion, and whether the valuation metrics reflect realistic expectations.

Hearing aid portfolio supports sales

Sonova’s representative product lines include advanced hearing aids and related accessories, such as rechargeable behind-the-ear devices, in-the-ear solutions, and wireless connectivity products that integrate with smartphones and televisions. These products, sold under well-known brand families, contribute significantly to the revenue figures discussed earlier and underpin the growth in Hearing Instruments and Audiological Care segments. In fiscal year 2024, unit sales of modern digital hearing aids rose year-on-year, and the share of rechargeable and Bluetooth-enabled models increased, supporting both average selling prices and customer satisfaction metrics. The technology evolution in Sonova’s product portfolio therefore plays a direct role in the quantified revenue growth powering Sonova stock.

Sonova stock and market valuation

Sonova shares trade on SIX Swiss Exchange under the symbol SOON, denominated in Swiss francs. The company’s market capitalization stands in the tens of billions of Swiss francs as of a recent trading date in 2026, placing it among the larger healthcare and medical technology issuers in Switzerland. The share price trades within a 52-week range that spans several tens of Swiss francs per share, from a lower bound that marked prior market corrections to a higher level reached around the time of stronger earnings releases. The current share price sits closer to the upper half of that 52-week range, reflecting how the market has digested the growth and margin story coming out of the latest fiscal year.